Yazılar

Ford Cuts Profit Outlook, Faces Stock Drop

/in /tarafından

Ford Motor Co. announced on Monday that it now anticipates meeting only the lower end of its full-year profit expectations, leading to a 5% dip in after-hours stock trading. The automaker forecasts annual earnings before interest and taxes (EBIT) around $10 billion, down from the previous $10-12 billion target.

Financial Performance and EV Adjustments

Despite its weakened forecast, Ford’s third-quarter earnings came in slightly better than expected, with adjusted profits of $0.49 per share compared to analysts’ projections of $0.47. However, net income dropped to $900 million, or $0.22 per share, from $0.30 per share a year ago, influenced by a $1 billion charge incurred after the cancellation of a three-row electric SUV in August.

CEO Jim Farley’s strategic cutbacks in Ford’s electric vehicle (EV) segment reflect intensified competition from Tesla and emerging Chinese EV brands. The scrapped three-row EV, once projected as a “personal bullet train,” was ultimately deemed unprofitable within the necessary timeframe for EV business sustainability.

EV Losses and Cost-Cutting Initiatives

Ford’s electric vehicle segment is projected to incur a $5 billion loss this year, with an EBIT loss of $1.2 billion in the third quarter alone, raising the segment’s total loss for 2024’s first three quarters to $3.7 billion. Although the company made cost improvements totaling nearly $1 billion over the past year, industry-wide pricing pressures have limited visible gains.

Looking ahead, Ford remains committed to cutting $2 billion in annual expenses by year-end through reductions in materials, manufacturing, and freight costs. Chief Financial Officer John Lawler noted that pricing pressures are likely to persist, potentially offsetting cost gains.

Market Reactions and Competitor Insights

Ford’s stock has declined 6% this year, a relatively smaller drop than Jeep-manufacturer Stellantis, whose shares have fallen by 40%. Conversely, General Motors has led the “Big Three” automakers in stock performance, with shares up 47% following robust earnings and consistently improved financial guidance.

 

Bristol Myers Squibb Beats Earnings Estimates and Raises Outlook Amid Cost-Cutting Measures

/in /tarafından

Bristol Myers Squibb reported strong second-quarter earnings, surpassing Wall Street expectations and raising its full-year guidance as part of its broader strategy to cut costs and reinvest in key drug brands and R&D programs. The pharmaceutical giant has outlined plans to reduce $1.5 billion in expenses by 2025, which includes laying off over 2,000 employees and consolidating its sites.

Key Financial Highlights:

  • Earnings per share: Adjusted EPS of $2.07, compared to an expected loss of $1.63.
  • Revenue: $12.2 billion, up 9% year-over-year, versus the expected $11.55 billion.
  • Net income: $1.68 billion, or 83 cents per share, down from $2.07 billion, or 99 cents per share, in the prior year.

Guidance Update:

  • Full-year revenue forecast: Now projected to increase at the “upper end” of the low single-digit range, up from a low single-digit increase.
  • Full-year adjusted earnings guidance: Raised to 60-90 cents per share, up from the previous forecast of 40-70 cents per share.

Shares of Bristol Myers rose nearly 8% following the earnings report.

Performance Drivers:

  • Eliquis: The blockbuster blood thinner recorded $3.42 billion in sales, a 7% increase year-over-year, aligning with analyst expectations. Eliquis, which Bristol Myers co-owns with Pfizer, is anticipated to lose market exclusivity by 2028.
  • Revlimid: Despite facing competition from generics, the blood cancer drug brought in $1.35 billion in sales, surpassing the estimated $1.09 billion.
  • Opdivo: The cancer drug generated $2.39 billion in sales, exceeding the expected $2.29 billion.

Growth Portfolio:

  • Reblozyl: Sales were above analysts’ expectations, contributing significantly to the company’s growth.
  • Opdualag and Camzyos: Both drugs, along with Opdivo, drove revenue growth within the portfolio.
  • Abecma: The cell therapy for multiple myeloma recorded $95 million in sales, close to the expected $95.8 million.

Bristol Myers continues to face pressure to innovate and introduce new drugs to compensate for revenue losses from key treatments like Revlimid, Eliquis, and Opdivo, which will eventually lose their market exclusivity.

The company’s proactive measures to cut costs and reinvest in strategic areas underscore its commitment to sustaining growth and competitiveness in the pharmaceutical industry.

CVS Slashes Profit Guidance Amid Rising Insurance Costs

/in /tarafından

CVS Health has significantly reduced its full-year profit forecast and announced a plan to cut $2 billion in expenses over several years. This comes as rising medical costs impact the company and the broader U.S. insurance industry. The cost-cutting measures aim to streamline operations, increase the use of artificial intelligence and automation, and reassess the business portfolio.

A major leadership change accompanied the announcement: Aetna President Brian Kane will leave the company immediately. CVS CEO Karen Lynch will take over the management of the insurance unit, assisted by CFO Thomas Cowhey and Katerina Guerraz, who will become the unit’s chief operating officer.

CVS now expects adjusted earnings for 2024 to be between $6.40 and $6.65 per share, down from a previous minimum of $7 per share. The company also reduced its unadjusted earnings guidance to $4.95 to $5.20 per share from at least $5.64 per share. This marks the third consecutive quarter of lowered profit guidance, reflecting ongoing pressures on its health insurance segment due to increased medical costs and unfavorable Medicare Advantage star ratings.

The health insurance division, which includes Aetna’s plans for the Affordable Care Act, Medicare Advantage, Medicaid, dental, and vision, is under strain. Medical costs in the second half of the year are expected to surpass those in the first half, potentially requiring a premium deficiency reserve to cover future claims and expenses.

The broader industry context is also challenging. Insurers like UnitedHealth Group, Humana, and Elevance Health are seeing increased medical costs as more Medicare Advantage patients resume procedures delayed during the pandemic. Medicare Advantage plans, though a growth driver, are facing cost concerns, which is troubling Wall Street.

In the second quarter, CVS reported adjusted earnings per share of $1.83, surpassing the expected $1.73, on revenues of $91.23 billion, slightly below the anticipated $91.5 billion. The company saw a net income of $1.77 billion, down from $1.90 billion a year earlier. While the insurance segment’s revenue rose over 21% to $32.48 billion, its operating income fell short of expectations, and the medical benefit ratio increased, indicating higher medical expenses relative to premiums.

CVS’s health services segment saw a revenue decline of nearly 9% year-over-year to $42.17 billion, despite higher-than-expected sales. The pharmacy and consumer wellness division’s sales increased by over 3% to $29.84 billion but fell short of expectations, driven by increased prescription volume amidst pressures from pharmacy reimbursement and the launch of new generic drugs.